Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable.
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Cyclin-Dependent Kinase Inhibitor p16
Female
Humans
Immunohistochemistry
Male
Middle Aged
Oncogene Proteins, Viral
/ immunology
Oropharyngeal Neoplasms
/ blood
Papillomaviridae
/ immunology
Papillomavirus Infections
/ blood
Repressor Proteins
/ immunology
Squamous Cell Carcinoma of Head and Neck
/ blood
Survival Rate
HPV16 E6
human papilloma virus
multiple imputation
oropharyngeal squamous cell carcinoma (OPSCC)
p16
serology
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
16
10
2018
revised:
28
01
2019
accepted:
12
02
2019
pubmed:
4
7
2019
medline:
19
5
2020
entrez:
4
7
2019
Statut:
ppublish
Résumé
In cancer epidemiological studies, determination of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OPSCC) typically depends on the availability of tumor tissue testing, and/or tumor tissue access. Identifying alternative methods for estimating HPV status can improve the quality of such studies when tissue is unavailable. We developed multiple predictive models for tumor HPV status and prognosis by combining both clinico-epidemiological variables and either serological multiplex assays of HPV or multiple imputation of HPV status (HPV
Substances chimiques
Antibodies, Viral
0
CDKN2A protein, human
0
Cyclin-Dependent Kinase Inhibitor p16
0
E6 protein, Human papillomavirus type 16
0
Oncogene Proteins, Viral
0
Repressor Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2166-2174Subventions
Organisme : NIDCR NIH HHS
ID : R01 DE025712
Pays : United States
Informations de copyright
© 2019 UICC.
Références
Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol 2014;50:380-6.
de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
Zaravinos A. An updated overview of HPV-associated head and neck carcinomas. Oncotarget 2014;5:3956-69.
Habbous S, Chu KP, Qiu X, et al. The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. Cancer Epidemiol 2013;37:820-9.
Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian cancer statistics 2016. Toronto, ON: Canadian Cancer Society, 2016.
Chan MW, Yu E, Bartlett E, et al. Morphologic and topographic radiologic features of human papillomavirus-related and -unrelated oropharyngeal carcinoma. Head Neck 2017;39:1524-34.
Habbous S, Chu KP, Lau H, et al. Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. CMAJ 2017;189:E1030-E40.
McCord C, Xu J, Xu W, et al. Association of high-risk human papillomavirus infection with oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:541-9.
Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013;31:2708-15.
Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005;51:1845-53.
Kreimer AR, Brennan P, Lang Kuhs KA, et al. Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J Clin Oncol 2015;33:877-84.
Brierley JD, MKG CW, eds. TNM classification of malignant tumours, 8th edn. Chichester, UK: Wiley, 2017. 241.
Amin MB, Edge S, Greene F, et al., eds. AJCC cancer staging manual, 8th edn. New York: Springer, 2017.
Venuti A, Paolini F. HPV detection methods in head and neck cancer. Head Neck Pathol 2012;6(Suppl 1):S63-74.
Holzinger D, Wichmann G, Baboci L, et al. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer 2017;140:2748-57.
Kreimer AR, Johansson M, Yanik EL, et al. Kinetics of the human papillomavirus type 16 E6 antibody response prior to oropharyngeal cancer. J Natl Cancer Inst 2017;109:djx005.
Lang Kuhs KA, Kreimer AR, Trivedi S, et al. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. Cancer 2017;123:4382-90.
Samuels SE, Eisbruch A, Beitler JJ, et al. Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we? Eur Arch Otorhinolaryngol 2015;273:2877-94.
Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142-8.
Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008;122:2656-64.
Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9.
Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:122-37.